Genomics and Systems Pharmacology Core

基因组学和系统药理学核心

• 批准号: 8763780
• 负责人: William Reinhold
• 金额: $ 12.04万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8763780
• 关键词: Binding; Bioinformatics; Biometry; Cancer Patient; Cancerous; Cell Line; Chemicals; Clinical Trials; Computer software; Country; Data; Data Set; Data Sources; Databases; Developmental Therapeutics Program; Extramural Activities; Genes; Genomics; Goals; Human; Individual; Internet; Laboratories; Lead; Location; Maintenance; Mammalian Cell; Maps; Metadata; Mining; Molecular; Molecular Biology; Online Systems; Pharmaceutical Preparations; Pharmacogenomics; Pharmacology; Research; Resources; Series; Site; System; anticancer activity; cancer cell; computer science; drug discovery; molecular scale; quality assurance; research study; therapy outcome; tool

We continue to maintain our Discover web-based tools (http://discover.nci.nih.gov/) for the scientific public. For data of the NCI-60 cancerous cell lines, our primary tool is CellMiner (http://discover.nci.nih.gov/cellminer/). Our main source of data comes from experiments in the 60 human cancer cells (the NCI-60), used by the NCI Developmental Therapeutics Program to screen 100,000 chemical compounds for anticancer activity since 1990. Our CellMiner "NCI-60 Analysis Tools" section is providing a significant resource for pharmacogenomic integration, research, and discovery. In addition, we host the scholarly molecular interaction maps of K. Kohn et al. The CellMiner data and tools are creating major opportunities for progress in rational drug discovery, application, and individualization of therapy for cancer patients. As molecular alterations of many types can contribute to the outcome of that therapy, the Genomic and Bioinformatics Group (GBG) manages and integrate molecular and pharmacological data in such a way that enhances understanding, and facilitates the generate testable hypotheses in the context of pharmacology. The GBG thus provides access to high throughput data in an integrative context, in addition to providing software resources that facilitate the understanding, mining and exploitation of these data. Using our expertise in molecular biology, molecular pharmacology, biostatistics, bioinformatics, and computer science, we have generated public databases, and software to query and mine those data. The drug database is continuously expanded by the DTP as new drugs enter clinical trials. Largely through studies at the GBG with its collaborators, the NCI-60 is by far the most comprehensively profiled panel of mammalian cells anywhere. Currently our Discover and CellMiner sites have 6,000 individual users from 73 countries per month. It has lead to two translational discoveries within the last year (see Accomplishments).

我们继续为科学公众维护基于Web的基于Web的工具（http://discover.nci.nih.gov/）。对于NCI-60癌细胞系的数据，我们的主要工具是CellMiner（http://discover.nci.nih.gov/cellminer/）。我们的主要数据来源来自NCI发育疗法计划使用的60个人类癌细胞（NCI-60）的实验，用于筛选自1990年以来的100,000种化合物，用于抗癌活性。我们的Cellminer“ NCI-60分析工具”部分为药物基因组一体化，研究，研究和发现提供了重要的资源。此外，我们拥有K. Kohn等人的学术分子相互作用图。 CellMiner数据和工具为癌症患者的治疗方法的合理药物发现，应用和个性化的进步创造了主要机会。由于许多类型的分子改变可以有助于该疗法的结果，因此基因组和生物信息学组（GBG）以增强理解并促进药理学背景下生成可检验的假设的方式来管理和整合分子和药理学数据。因此，GBG除了提供促进对这些数据的理解，采矿和开发的软件资源之外，还提供了对集成环境中高​​吞吐量数据的访问。利用我们在分子生物学，分子药理学，生物统计学，生物信息学和计算机科学方面的专业知识，我们已经生成了公共数据库和软件来查询和挖掘这些数据。随着新药物进入临床试验，DTP不断扩大药物数据库。 NCI-60在很大程度上是通过GBG的研究，是迄今为止在任何地方的哺乳动物细胞面板最全面的。目前，我们的发现和Cellminer网站每月有6,000名来自73个国家 /地区的个人用户。它导致了去年的两个翻译发现（请参阅成就）。